The new guideline offers multi-pronged, evidence-based clinical practice recommendations. Among the guidance includes:
- All patients with a current or previous diagnosis of invasive breast cancer ≤ 65 years should be offered BRCA1/2 testing.
- All patients with a current or previous diagnosis of invasive breast cancer > 65 years should be offered BRCA1/2 testing if personal or family history suggests the possibility of a pathogenic variant or are candidates for a PARP inhibitor therapy.
- Testing for high and moderate penetrance breast cancer genes beyond BRCA1/2 can inform medical therapy, influence surgical decision-making, refine risk estimates for future cancers, inform family members, and should be offered to appropriate patients.
- Patients undergoing genetic testing should be given sufficient information before testing to provide informed consent. Formal genetic counseling sessions may not always be possible, and several alternative approaches exist.
“ASCO-SSO’s guideline update is an important step forward in advancing the use of genomics in clinical care for patients with breast cancer,” said
Myriad’s germline test, MyRisk® Hereditary Cancer Test, analyzes 48 genes linked to 11 cancer types including breast cancer. Germline testing can help guide more personalized treatment decisions, including targeted therapies and surgical techniques.
About
Safe Harbor Statement
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including the statement that the latest clinical practice recommendations expand access to genetic testing and limit barriers to care. These “forward-looking statements” are management’s expectations of future events as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially and adversely from those anticipated. Such factors include those risks described in the company’s filings with the
Investor Contact
(801) 584-3532
IR@myriad.com
Media Contact
(385) 318-3718
PR@myriad.com
Source:
2024 GlobeNewswire, Inc., source